Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 6/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268774 | 0.90 | CNR1 (0.36) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31269337 | 0.88 | CNR1 (0.39) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31269020 | 0.85 | FFAR4 (0.38) | CNR1SLC22A12FFAR1PIK3CDFFAR4 | |
| SCHEMBL31269235 | 0.84 | CNR1 (0.38) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31269364 | 0.83 | CNR1 (0.37) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31269055 | 0.83 | CNR1 (0.36) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31268800 | 0.82 | CNR1 (0.38) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31268994 | 0.82 | CNR1 (0.38) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31268892 | 0.82 | CNR1 (0.37) | CNR1PIK3CDDPP4CYP3A4GPR119 | |
| SCHEMBL31268744 | 0.82 | CNR1 (0.37) | CNR1PIK3CDDPP4CYP3A4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |